A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Status:
Completed
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the administration of AdV-tk followed by valacyclovir in children
with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma
(AA), as well as recurrent ependymomas in combination with radiation therapy. The primary
objective is to determine if this approach is safe and can be effectively delivered without
disturbing standard therapy.
Phase:
Phase 1
Details
Lead Sponsor:
Advantagene, Inc. Candel Therapeutics, Inc.
Collaborators:
Boston Children's Hospital Boston Children’s Hospital